Prestige Consumer Healthcare Inc.

Fundamentals6.0
Price Action2.0
News Sentiment3.0
AI Rating
4.0

Key Drivers

  • Strong Margins
  • Solid Liquidity
  • Intangible Risk

AI
AI Summary

4.0

PBH is no longer a simple defensive cash compounder—it is now a “show-me” story where strong cash flow and decent balance-sheet resilience are offset by earnings misses, margin compression, and legal overhang, so the stock likely needs clear execution on integration, supply normalization, and margin recovery before it can re-rate.

ExecutionRisk
MarginPressure
CashFlow‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Strong Margins
  • Solid Liquidity
  • Intangible Risk

PBH looks fundamentally solid thanks to strong margins, cash flow, and liquidity, but its case is tempered by intangible-heavy assets, moderate capital efficiency, and limited hard-asset backing.

cashflow
intangibles

Price Behavior

2.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Failed rebound
  • Near-term resistance

Over the last month, PBH has trended sharply lower with lower highs/lows, failed rebounds in the low-50s, and now faces near-term resistance at $50-$52 and stronger resistance at $55-$56 while $46 remains tentative support.

bearish
downtrend
Support Level: $46
Resistance Level: $50-$52

Sharp decline from late-April highs near $58-$59, with only a modest bounce that failed to hold above the low-50s

Sentiment & News

3.0

Key News Insights:

  • Earnings miss
  • Acquisition deal
  • Legal scrutiny

Prestige Consumer Healthcare's Q4 earnings missed estimates, revenue came in soft, and a new acquisition was overshadowed by share weakness and a securities-law investigation, keeping sentiment negative.

earnings
investigation

The news is likely to weigh on PBH shares near term as weak results and regulatory concerns outweigh the strategic benefits of the acquisition